{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:49:22Z","timestamp":1780552162778,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.10.039","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T18:04:24Z","timestamp":1603130664000},"page":"7697-7701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein"],"prefix":"10.1016","volume":"38","author":[{"given":"Daisuke","family":"Muraoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Situo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naozumi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.10.039_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.10.039_b0010","doi-asserted-by":"crossref","unstructured":"Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727\u201333. http:\/\/doi: 10.1056\/NEJMoa2001017.","DOI":"10.1056\/NEJMoa2001017"},{"key":"10.1016\/j.vaccine.2020.10.039_b0015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0307140101","article-title":"Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association","author":"Sui","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2020.10.039_b0020","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2018.1506702","article-title":"Prospects for a MERS-CoV spike vaccine","author":"Zhou","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"281\u20132","key":"10.1016\/j.vaccine.2020.10.039_b0025","article-title":"Function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2020.10.039_b0030","doi-asserted-by":"crossref","unstructured":"Hassan AO, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 2020 [in press]. http:\/\/doi: 10.1016\/j.cell.2020.06.011.","DOI":"10.1016\/j.cell.2020.06.011"},{"key":"10.1016\/j.vaccine.2020.10.039_b0035","doi-asserted-by":"crossref","unstructured":"Long QX, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020 [in press]. http:\/\/doi: 10.1038\/s41591-020-0965-6.","DOI":"10.1038\/s41591-020-0965-6"},{"issue":"1489\u2013501","key":"10.1016\/j.vaccine.2020.10.039_b0040","first-page":"e1415","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2020.10.039_b0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-020-00263-y","article-title":"Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2020.10.039_b0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-020-0798-y","article-title":"T cells in COVID-19 \u2014 united in diversity","author":"Swadling","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2020.10.039_b0055","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.181.8.5490","article-title":"T cell responses to whole SARS coronavirus in humans","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.10.039_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.039_b0065","doi-asserted-by":"crossref","unstructured":"Chandrashekar A, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 2020 [in press]. doi: 10.1126\/science.abc4776.","DOI":"10.1126\/science.abc4776"},{"key":"10.1016\/j.vaccine.2020.10.039_b0070","doi-asserted-by":"crossref","unstructured":"Yu J, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020 [in press]. http:\/\/doi: 10.1126\/science.abc6284.","DOI":"10.1126\/science.abc6284"},{"key":"10.1016\/j.vaccine.2020.10.039_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2005.01.050","article-title":"Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein","author":"Zhi","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.10.039_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2172-13-50","article-title":"Residue analysis of a CTL epitope of SARS-CoV spike protein by IFN-gamma production and bioinformatics prediction","author":"Huang","year":"2012","journal-title":"BMC Immunol."},{"key":"10.1016\/j.vaccine.2020.10.039_b0085","doi-asserted-by":"crossref","unstructured":"Bao L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020 [in press]. http:\/\/doi: 10.1038\/s41586-020-2312-y.","DOI":"10.1038\/s41586-020-2312-y"},{"key":"10.1016\/j.vaccine.2020.10.039_b0090","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-04-2585","article-title":"Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE","author":"Miyahara","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:47:39Z","timestamp":1759402059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":18,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20313335"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}